SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-074097
Filing Date
2022-03-14
Accepted
2022-03-14 08:09:01
Documents
14
Period of Report
2022-03-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d282563d8k.htm   iXBRL 8-K 25054
2 EX-99.1 d282563dex991.htm EX-99.1 54081
6 GRAPHIC g282563g0314083409312.jpg GRAPHIC 3567
  Complete submission text file 0001193125-22-074097.txt   212450

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fstx-20220314.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20220314_lab.xml EX-101.LAB 17168
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20220314_pre.xml EX-101.PRE 10787
8 EXTRACTED XBRL INSTANCE DOCUMENT d282563d8k_htm.xml XML 3272
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 22735127
SIC: 2834 Pharmaceutical Preparations